Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03113071 · ClinicalTrials.gov registry record · Phase 1
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03113071: Clinical Trial Phase 1 study, sponsored by Fox Chase Cancer Center.
NCT03113071 is a Phase 1 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03113071, a Phase 1 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary hypothesis is that digoxin can be safely added to decitabine and will increase the response rates in medically unfit patients with newly diagnosed AML/MDS or those with relapsed/refractory AML/MDS. Furthermore, it is hypothesized that the addition of digoxin to decitabine will result in distinct epigenetic alterations in AML/MDS patients.
Primary Outcome
Maximum tolerated dose of digoxin in combination with standard dose of decitabine will be determined by a standard 3+3 dose de-escalation design
Interventions
- DRUG Decitabine
- DRUG Digoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-06-02 |
| Est. Completion | 2019-03-11 |
| Phase | Phase 1 |
Why NCT03113071 stopped before completion
NCT03113071 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Decitabine is the first listed.
NCT03113071 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03113071 about?
NCT03113071 is a clinical study titled "Safety and Activity of Digoxin With Decitabine in Adult AML and MDS". The primary hypothesis is that digoxin can be safely added to decitabine and will increase the response rates in medically unfit patients with newly diagnosed AML/MDS or those with relapsed/refractory AML/MDS. Furthermore, it is hypothesized that the addition of digoxin to decitabine will result in ...
What is the current status of trial NCT03113071?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2017-06-02. Estimated completion is 2019-03-11.
What interventions are being tested in trial NCT03113071?
The interventions under investigation include: Decitabine (DRUG), Digoxin (DRUG).
Who is sponsoring clinical trial NCT03113071?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03113071's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI